October 25, 2019

White House Reviewing Importation Notice, Framework Forthcoming

Libby Baney and Matthew Rubin examined an October 7, 2019, draft guidance from the U.S. Department of Health and Human Services (HHS). The draft guidance is likely connected to Pathway 2 of HHS' Safe Importation Action Plan, which intends to "provide domestic pharmaceutical manufacturers the ability to re-import FDA-approved prescription drugs sold in other countries through the creation of a new national drug code (NDC), labeling, and identification in compliance with the Federal Food, Drug and Cosmetics Act."
Full Article
The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.